GHRH Antagonist JMR-132 Blocks Both ER-Positive and ER-Negative Breast Cancer Cell Proliferation
Background
Breast cancer treatment is complicated by tumor heterogeneity, particularly the division between estrogen receptor (ER)-positive and ER-negative subtypes, which respond differently to endocrine therapies. GHRH antagonists have previously demonstrated inhibition of various human cancer xenografts in nude mice, including ER-negative breast cancers, suggesting a growth-hormone-axis-independent oncological role. Critically, GHRH is locally produced in diverse neoplasms, including breast cancer, raising the possibility that autocrine or paracrine GHRH signaling directly drives tumor cell proliferation via the GHRH-receptor. The existence of a pituitary-type GHRH-R on tumor cells themselves — rather than only on pituitary somatotrophs — opens a direct, receptor-mediated antiproliferative target. Prior work had not established whether GHRH antagonism could suppress growth uniformly across ER-defined breast cancer subtypes, leaving a critical gap for receptor-agnostic therapeutic strategies.
Study Design
Researchers tested JMR-132, a novel highly potent GHRH antagonist, against two human breast cancer cell lines in vitro: the ER-negative SKBR 3 line and the ER-positive ZR 75 line. Proliferation assays measured the direct effect of JMR-132 in the absence of exogenous GHRH, and also following direct stimulation with GHRH(1-29)NH2 (the natural ligand fragment). Expression of both the GHRH ligand and the pituitary-type GHRH-R in each cell line was confirmed. A key endpoint was whether JMR-132 could nullify the proliferative response to GHRH stimulation in both cell lines, and whether its antiproliferative activity persisted even without added GHRH, establishing receptor-dependent autonomous activity.
Results
Both SKBR 3 and ZR 75 cell lines expressed the GHRH ligand endogenously and the pituitary-type GHRH-R, indicating intrinsic autocrine signaling capacity. Direct stimulation with GHRH(1-29)NH2 increased proliferation in both ER-negative SKBR 3 and ER-positive ZR 75 lines, confirming functional receptor activation. JMR-132 demonstrated significant antiproliferative activity in both lines even in the absence of exogenous GHRH, suggesting constitutive or autocrine GHRH-R activity drives baseline proliferation. Critically, JMR-132 completely nullified the proliferative effect of exogenous GHRH stimulation in both cell lines.
JMR-132 exerted strong antiproliferative activity independent of estrogen receptor status, blocking GHRH-driven growth in both ER-positive ZR 75 and ER-negative SKBR 3 human breast cancer cells.
The finding that antiproliferative effects occurred even without added GHRH implies that endogenous, locally produced GHRH provides a tonic growth signal in these tumor cells that JMR-132 interrupts via the GHRH-R.
Key Findings
- JMR-132 inhibited proliferation of ER-negative SKBR 3 cells in vitro, independent of exogenous GHRH.
- JMR-132 inhibited proliferation of ER-positive ZR 75 cells in vitro, independent of exogenous GHRH.
- GHRH(1-29)NH2 stimulation increased proliferation in both SKBR 3 and ZR 75 cell lines.
- JMR-132 fully nullified the proliferative effect of GHRH in both cell lines.
- Both cell lines expressed endogenous GHRH ligand and the pituitary-type GHRH-receptor.
Why It Matters
GHRH antagonism via JMR-132 may represent a receptor-status-agnostic therapeutic axis in breast cancer, addressing a major clinical gap: ER-negative tumors have few hormone-based treatment options. The dual activity — suppressing both basal and GHRH-stimulated growth — suggests local autocrine GHRH signaling is a meaningful proliferative driver that current endocrine therapies do not address. For clinicians and researchers, this raises the prospect of combining GHRH antagonists with existing anti-estrogen protocols (e.g., aromatase inhibitors or SERMs) to achieve complementary pathway inhibition. Combination treatment targeting both the estrogen pathway and GHRH-R may improve outcomes across breast cancer subtypes. Translation to clinical protocols remains early-stage — in vitro data must be followed by xenograft and eventually human trial evidence before dosing recommendations are possible.
